Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Sees Significant Increase in Short Interest

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) was the target of a significant increase in short interest in July. As of July 15th, there was short interest totaling 9,026 shares, an increase of 319.0% from the June 30th total of 2,154 shares. Based on an average daily trading volume, of 90,174 shares, the days-to-cover ratio is currently 0.1 days.

Ono Pharmaceutical Stock Performance

Shares of OTCMKTS:OPHLY traded up $0.00 on Monday, hitting $4.93. The company’s stock had a trading volume of 16,364 shares, compared to its average volume of 32,146. The company has a 50-day simple moving average of $4.84 and a 200 day simple moving average of $5.00. Ono Pharmaceutical has a 1 year low of $3.55 and a 1 year high of $5.75.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.

In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.